spacer
home > ebr > Autumn 2012
PUBLICATIONS

European Biopharmaceutical Review

ebr
Autumn 2012

   
Text
PDF
BioBusiness, Finance & Communication
Incentivising R&D

Patent versus Patient

Nick Beckett of CMS Cameron McKenna examines the complex interface of intellectual property and competition law, and weighs up these very different approaches to stimulating innovation in the biotech sector.
 
view
download pdf
Spotlight

Open Innovation

Thomas Bombelles of the World Intellectual Property Organization presents the initiatives coordinated by the consortium WIPO Re:Search in their attempt to promote research into neglected tropical diseases through shared intellectual property.
 
view
download pdf
Identity Trust

Sign on the Digital Line

Being able to reliably identify a digital contact is essential to business in the current global market. Mollie Shields-Uehling of SAFE-BioPharma Association examines an industry-wide approach designed to build this trust.
 
view
download pdf
bullet
BioResearch and Innovation
Monoclonal Antibodies

Hitting the Target

Zhengbin (Bing) Yao of MedImmune takes a look at the advantages of mAb therapy to respiratory, infl ammatory and autoimmune (RIA) diseases, and reviews some key early mAb entrants into the RIA market.
 
view
download pdf
Targeted Cancer Therapeutics

Resisting Mutation, Restricting Resistance

William C Shakespeare of ARIAD Pharmaceuticals, Inc explores the mechanisms of resistance and next-generation agents in development for biomarker-driven, targeted non-small cell lung cancer therapeutics, several of which are designed specifically to target disease-resistant mutations.
 
view
download pdf
Biological Wound Care

A Topical Subject

Wound care is a growing business; competition is on the rise and differentiation will be the key to success. The future, argues Paul Titley of Aesica, lies in biologics, gene therapy and specific cell-based therapies for molecular and genomic deficiencies.
 
view
download pdf
bullet
Discovery Technology
MRI

A Secret Weapon

Recent developments in magnetic resonance imaging that have unlocked stronger field strengths and increased sensitivity. Ross McLennan at Brains Unlimited explores how this technology can enhance our understanding of the disease and aid target identification.
 
view
download pdf
Digital Pathology

Picture Perfect

Digital pathology has emerged as a core technology for drug discovery and the development of new tissue diagnostic tests. Peter Hamilton of PathXL Ltd examines just how this technology can offer improved efficiency, workflow and interoperability.
 
view
download pdf
Sample Management

A Store Point

High-quality samples are an invaluable asset for biomarker discovery and drug development. Kristina Robson of BioStorage Technologies illustrates how samples can be handled and stored with good storage practices to ensure their integrity is maintained for current and future research.
 
view
download pdf
Paperless Labs

In with the New

The demand for paperless labs to bring together isolated silos of information and establish new found efficiencies has never been greater. Susan Najjar of Thermo Fisher Scientific considers the factors to bear in mind when selecting a system.
 
view
download pdf
BioDevelopment
Drug Induced Liver Injury

Mindful Medical Monitoring

Akhil Kumar, Maxim Kosov, Marcelo Yantorno and Maxim Belotserkovsky at PSI CRO AG explore the complex subject of drug induced liver injury and the impact of false diagnoses on clinical trials.


 
view
download pdf
bullet
BioFormulation and Manufacturing
Biomanufacturing: Prophages

The Good, the Bad and the Ugly

When considering lysogenic bacteria as a host in biomanufacturing, it is essential to maintain a high degree of care during construction of the production process and ensure that well developed control tests and procedures are in place, as Marcin Los of Phage Consultants demonstrates.

 
view
download pdf
Getting Specific

Analytical Methods: Host Cell Proteins

Olaf Stamm, Mark Jostameling, Stephanie Graze and Simone Scotti of Charles River weigh up the benefits of generic and product-specific assays for the quantitative analysis of residual host cell proteins.



 
view
download pdf
Reinventing the Column

Analytical Methods: UHPLC

Existing analytical analysis solutions have proven inadequate for the new generation of complex protein therapeutics. Michael McGinley of Phenomenex Inc examines advances made by new UHPLC column technology that can stand up to the challenge.
 
view
download pdf
   
spacer
Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July and October

News and Press Releases

New to the PPMA Show 2018: Bright Ideas - Ambassador Programme

A new initiative for PPMA Show visitors this year is the Bright Ideas - Ambassador Programme - a free advice service for start-up ventures and entrepreneurs.
More info >>

White Papers

The BioPharmaSpec Approach”: Mass Spectrometry Based Host Cell Protein Identification and Quantitation

BioPharmaSpec

1. Introduction As part of the development of any biopharmaceutical product, the impurities present must be examined, minimized and where possible characterized (1). These impurities fall into two broad categories: product-related impurities (derived specifically from the drug product itself) and process-related impurities (derived from material associated with the production, processing or purification of the sample). Host cell proteins (HCPs) are process-related impurities that require specific analysis due to the multitude of naturally occurring proteins expressed in the production cell line.
More info >>

Industry Events

Pharma and Device Packaging and Labelling West Coast 2018

27-28 November 2018, Burlingame, CA

The second edition of the Pharma and Device Packaging and Labeling West Coast was a thought-provoking two days of engaging presentations, discussion and networking.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement